Bernie, here are my thoughts on the following paragraphs from your post:
1. "(ii) an injunction against Advanced Viral from further attempts to use, market or assert any claims of ownership over any broad/exclusive rights in Reticulose, or the use, publication or disclosure of information regarding Reticulose;"
As I noted in an earlier post this morning, the absence of the word "Reticulose" was very evident in Dr. Hirschman's interview of today. How may posts have we seen on a number of threads trying to convince us that Product R is something different from Reticulose. It would appear that if Product R is significantly different or better than Reticulose, the question as to who has the rights to Reticulose becomes a mute point, don't you think?
2. "does anyone know (or find out) if this suit is in any way delaying any of the ongoing drug application processes? Does this suit have to be settled BEFORE any IND can be filed?"
In talking to ADVR south via phone the answer to these questions was that the law suit(s) will in no way delay the IND application.
3. Will this suit impact in any way the possibility of attracting investors, possible partners and other integral personnel to the company??
With regard to attracting investors — well the first day the litigation was made public in the SEC document the stock hit a lower low in its downward trend. IMO, this litigation, like any litigation, should not help in attracting investors until it is resolved.
With regard to possible partners — that depends in how convincing Dr. Hirschman can be in selling a deal with a bomb under his chair. After all, he has been successful in selling some more shares. |
